Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
about
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondCodon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.mRNA-based dendritic cell vaccines.The ReNAissanCe of mRNA-based cancer therapy.mRNA transcript therapy.Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression.Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cellsTargeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 MastocytomaEngineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.In vitro synthesis of modified mRNA for induction of protein expression in human cells.Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
P2860
Q26861563-31ED1A3C-0D23-456F-8DBE-0584708EEC6AQ35208290-8082C29A-2F66-4F08-A003-0E3CD7D7B99BQ36107961-DDE357FB-F173-4D2F-A92F-3AA6C4EEF2A7Q38246769-B8CD08F1-459B-465B-A732-2F0AFFC81200Q38255012-76D66EA1-A5B3-4507-BB9E-6D56BAD92585Q38264088-C79EF40E-F8F8-45F2-B8D6-7E90C971B2F3Q38617089-7657B344-B7D4-4427-AC98-7DA3711BBCC7Q38850538-7A784C01-CAC2-4855-A7E8-08C54B23D813Q39360428-F47E08FF-D7C7-4D4B-8E5E-19B753148338Q40452198-9724DA47-8DB7-4313-A3A8-C3C73663647EQ41191220-9684AC65-B6E1-4E22-B585-C10CE32BC97AQ41343094-3B1B9A75-8FE7-4E1B-9E34-A9E3C0FDB060Q43181174-6D81882A-9CD6-4D73-886B-1D1EA4483406Q43297784-EEB54A53-88AD-4E84-AA3C-E8477D8C80D6Q51313262-E09DD247-2D4E-49DF-A8CD-C98E29AB4F6AQ52846347-5B872D9B-00BB-4432-9911-8FC9994D08AAQ55003884-04FD2E01-3C84-4346-8835-6830027E27C9Q59125585-7624DCCB-8A16-4464-A45F-2832A5B616CD
P2860
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Design of an Optimized Wilms' ...... ogenicity In Vitro and In Vivo
@en
Design of an Optimized Wilms' Tumor 1
@nl
type
label
Design of an Optimized Wilms' ...... ogenicity In Vitro and In Vivo
@en
Design of an Optimized Wilms' Tumor 1
@nl
prefLabel
Design of an Optimized Wilms' ...... ogenicity In Vitro and In Vivo
@en
Design of an Optimized Wilms' Tumor 1
@nl
P2093
P2860
P50
P356
P1476
Design of an Optimized Wilms' ...... ogenicity In Vitro and In Vivo
@en
P2093
Carlo Heirman
Daphné Benteyn
Jurgen Corthals
Katrien Van Beneden
Kris Thielemans
Sandra Van Lint
Sébastien Anguille
Viggo Van Tendeloo
P2860
P356
10.1038/MTNA.2013.54
P577
2013-11-19T00:00:00Z